Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.
COVID-19
SARS-COV-2
cohort
coronavirus
fluvoxamine
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
21
12
2020
accepted:
27
01
2021
entrez:
24
2
2021
pubmed:
25
2
2021
medline:
25
2
2021
Statut:
epublish
Résumé
We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to receive fluvoxamine (50 mg twice daily) and 48 declined. Incidence of hospitalization was 0% (0 of 65) with fluvoxamine and 12.5% (6 of 48) with observation alone. At 14 days, residual symptoms persisted in 0% (0 of 65) with fluvoxamine and 60% (29 of 48) with observation.
Identifiants
pubmed: 33623808
doi: 10.1093/ofid/ofab050
pii: ofab050
pmc: PMC7888564
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab050Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Sci Transl Med. 2019 Feb 6;11(478):
pubmed: 30728287
JAMA. 2020 Dec 8;324(22):2292-2300
pubmed: 33180097
Circulation. 2020 Dec 17;:
pubmed: 33327727